Abstract
Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have